Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26773080 | 1.00 | GRM5 (0.43) | GRM5GABRA5KDM4EHPGDRAB9A | |
| SCHEMBL30486321 | 0.91 | GRM5 (0.53) | GRM5KDM4EHPGDRAB9AALDH1A1 | |
| SCHEMBL26775594 | 0.91 | GRM5 (0.53) | GRM5KDM4EHPGDRAB9AALDH1A1 | |
| SCHEMBL30486360 | 0.90 | GRM5 (0.44) | GRM5KDM4ERAB9A | |
| SCHEMBL26773005 | 0.90 | GRM5 (0.44) | GRM5KDM4ERAB9A | |
| SCHEMBL30486381 | 0.88 | KDM4E (0.52) | GRM5KDM4ERAB9AALDH1A1 | |
| SCHEMBL26773033 | 0.88 | KDM4E (0.52) | GRM5KDM4ERAB9AALDH1A1 | |
| SCHEMBL26773084 | 0.87 | JAK2 (0.43) | HPGDALDH1A1 | |
| SCHEMBL30486307 | 0.87 | GRM5 (0.46) | GRM5KDM4EHPGDALDH1A1POLB | |
| SCHEMBL26773057 | 0.87 | GRM5 (0.46) | GRM5KDM4EHPGDALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192464-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Origenis GmbH (DE) | 2023-06-14 | — | — | EP | claimed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, MAPKAPK2, MAP3K20 | GRM5 1666/4885GABRA5 2230/4885KDM4E 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.